{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Ursodeoxycholic Acid for Gallstone Prevention Post-Gastrectomy"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "multicenter, randomised, double-blind, placebo-controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Adults (\u226519 years) with gastric cancer undergoing gastrectomy were enrolled from May 26, 2015, to January 9, 2017."
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1:1 to receive 300 mg UDCA, 600 mg UDCA, or placebo daily for 52 weeks"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the efficacy and safety of ursodeoxycholic acid (UDCA) in preventing gallstone formation in gastric cancer patients post-gastrectomy."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was gallstone formation within 12 months, assessed by ultrasonography."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation used a stratified block method, and allocation was concealed via an interactive web-response system."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included participants, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Of 521 randomised patients, 465 were analysed"
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "465 were analysed (151 in 300 mg group, 164 in 600 mg group, 150 in placebo group) using intention-to-treat."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Odds ratios were 0.27 (95% CI, 0.12-0.62; P = .002) for 300 mg and 0.20 (95% CI, 0.08-0.50; P < .001) for 600 mg."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant adverse reactions were reported. The most common adverse event was nausea (0.8%), with no serious adverse reactions."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: NCT02490111."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 24,
    "max_score": 25
  },
  "model": "gpt-4o"
}